Eli Lilly Scales Back Planned Virginia Insulin Plant
Eli Lilly Scales Back Planned Virginia Insulin Plant
Indianapolis-based Eli Lilly and Co. has halved its planned insulin plant in Prince William County, Virginia, according to a Washington Post report (confirmed by a Lilly spokesperson), which appeared yesterday. The proposed plant is also two years behind schedule.
In a meeting yesterday with the Board of County Supervisors, the Post reported, company officials said they now intend to hire only half the approximately 700 workers originally planned and will reduce the planned 600,000-ft² complex to 300,000 ft². Construction is now expected to begin this winter, and the plant should be fully operational by 2009.
The news report cited increasing costs of steel and other building materials as a major reason for the cutback and the delay in the construction start. Industry analysts linked the decision to erosion in Lilly’s insulin market share and declining sales of one of the company’s insulin products, Humulin.
–Laura Bush
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
